JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report

被引:3
|
作者
Yhim, Ho-Young [1 ]
Kim, Hee Sun [4 ]
Sohn, Ji-Youn [1 ]
Song, Min-Ju [1 ]
Lee, Na-Ri [1 ,3 ]
Song, Eun-Kee [1 ,3 ]
Choi, Sam-Im [2 ]
Yim, Chang-Yeol [1 ,3 ]
Kwak, Jae-Yong [1 ,3 ]
机构
[1] Chonbuk Natl Univ, Sch Med, Dept Internal Med, Div Hematol Oncol, Jeonju 561712, South Korea
[2] Chonbuk Natl Univ, Sch Med, Dept Lab Med, Jeonju 561712, South Korea
[3] Chonbuk Natl Univ, Sch Med, Adv Res Canc Ctr, Jeonju 561712, South Korea
[4] Jeonbuk Sci Coll, Dept Nursing, Jeongeup 580712, South Korea
关键词
TYROSINE KINASE JAK2; CANCER INCIDENCE; MYELOID METAPLASIA; MUTATION; MEN;
D O I
10.1016/j.cancergencyto.2010.01.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Klinefelter syndrome (KS) is the most commonly diagnosed X chromosome aneuploid syndrome among males. The association between hematologic malignancies such as non-Hodgkin lymphoma and leukemia and KS has been established recently on the basis of numerous case reports and a large cohort study. The risk of chronic myeloproliferative disease (MPD) as a hematologic malignancy in KS, however, has not been evaluated to date. Moreover, to our knowledge, there is only one case report that observed MPD in a patient with KS. Even though the Janus kinase 2 (JAK2) mutation was considered the primary cause in the pathogenesis of MPD, the mutation status was not described in that report. We found JAK2 V617F mutation-positive essential thromobocythemia (ET) in a patient with KS. To the best of our knowledge, this case represents the first case report of JAK2 V617F mutation in a patient with KS. Furthermore, we also suggest the hypothesis that X chromosome aneuploidy as a "pre-JAK2" cytogenetic change may be associated with the development of clonal hematopoiesis and carcinogenesis, because of the finding of higher oncogenic potential of extra X chromosome. In this study, we present the first report of JAK2 V617F-positive ET in a patient with KS, as well as a review of the relevant literature. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:162 / 165
页数:4
相关论文
共 50 条
  • [1] JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia A case report
    Oda, Yasuhiro
    Sato, Shuku
    Kanbe, Emiko
    Kamata, Wataru
    Okada, Satomi
    Tamai, Yotaro
    MEDICINE, 2019, 98 (44) : e17766
  • [2] Acute Transmural Myocardial Infarction by Coronary Embolism in a Patient with JAK2 V617F-Positive Essential Thrombocythemia
    Loria, Johannes Rotta Detto
    Rawluk, Justyna
    Krauss, Tobias
    Bode, Christoph
    Moser, Martin
    Helbing, Thomas
    HAMOSTASEOLOGIE, 2018, 38 (02): : 106 - 111
  • [3] Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
    Lee, A-Jin
    Kim, Sang-Gyung
    Nam, Jun Yeb
    Yun, Jaehum
    Ryoo, Hun-Mo
    Bae, Sung Hwa
    BLOOD RESEARCH, 2021, 56 (04) : 259 - 265
  • [4] JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia
    Li, Juan
    Spensberger, Dominik
    Ahn, Jong Sook
    Anand, Shubha
    Beer, Philip A.
    Ghevaert, Cedric
    Chen, Edwin
    Forrai, Ariel
    Scott, Linda M.
    Ferreira, Rita
    Campbell, Peter J.
    Watson, Steve P.
    Liu, Pentao
    Erber, Wendy N.
    Huntly, Brian J. P.
    Ottersbach, Katrin
    Green, Anthony R.
    BLOOD, 2010, 116 (09) : 1528 - 1538
  • [5] JAK2 V617F mutation to calreticulin mutation in an essential thrombocythemia patient: A case report
    Wang, Su-Yun
    Yang, Ning
    Zhang, Li-Jun
    Cheng, Zhi-Yong
    INDIAN JOURNAL OF CANCER, 2021, 58 (03) : 431 - 433
  • [6] The JAK2 V617F mutation in essential thrombocythemia
    Cho, Young-Uk
    Chung, Hee-Jung
    Chi, Hyun-Sook
    Jang, Seoungsoo
    Park, Chan-Jeoung
    Lee, Jung-Hee
    Lee, Je-Hwan
    Lee, Kyoo-Hyung
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2007, 29 : 103 - 103
  • [7] A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate
    Ebisawa, Kazutoshi
    Masamoto, Yosuke
    Yagi, Koichi
    Kurokawa, Mineo
    ANNALS OF HEMATOLOGY, 2022, 101 (11) : 2551 - 2552
  • [8] A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate
    Kazutoshi Ebisawa
    Yosuke Masamoto
    Koichi Yagi
    Mineo Kurokawa
    Annals of Hematology, 2022, 101 : 2551 - 2552
  • [9] Gender Is a Phenotypic Modifier in the JAK2 V617F-Positive MPD
    Stein, Brady L.
    Williams, Donna
    Rogers, Ophelia
    Isaacs, Mary Ann
    Pemmaraju, Naveen
    Moliterno, Alison R.
    BLOOD, 2008, 112 (11) : 622 - 622
  • [10] Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies
    Veselovska, Jitka
    Pospisilova, Dagmar
    Pekova, Sona
    Horvathova, Monika
    Solna, Renata
    Cmejlova, Jana
    Cmeila, Radek
    Belickova, Monika
    Mihal, Vladimir
    Stary, Jan
    Divoky, Vladimir
    LEUKEMIA RESEARCH, 2008, 32 (03) : 369 - 377